IN the previous post about the "SCOracle" case [1, 2, 3, 4, 5, 6, 7] we attempted to find an explanation for Oracle harming its own asset, or at least looking to reduce fragmentation. Oracle has a history of opposing software patents (based on a statement pulled from many years ago) and its recently inherited product, ZFS, is still under attack by software patents.
In a motion filed quietly in late June, Christopher Hansen of the American Civil Liberties Union and Daniel Ravicher claim that remarks made by Federal Circuit Chief Judge Randall Rader at a biotechnology industry event show he may have a biased view of the case in question, Association of Molecular Pathology et. al. v. U.S. Patent and Trademark Office et. al, and should not be one of the three judges to decide the appeal.
Questioning Rader's objectivity is an unusual move that underscores just how high the stakes are in the case at issue, in which several doctors' groups have joined the ACLU and PubPat in seeking to invalidate patents on two genes related to breast cancer that are owned by Utah-based Myriad Genetics--and, more broadly, to challenge the legality of the thousands of genetic patents already in existence.